1. Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial
- Author
-
Bokoch, Michael P, Tran, Amy T, Brinson, Erika L, Marcus, Sivan G, Reddy, Meghana, Sun, Elizabeth, Roll, Garrett R, Pardo, Manuel, Fields, Scott, Adelmann, Dieter, Kothari, Rishi P, and Legrand, Matthieu
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Organ Transplantation ,Transplantation ,Clinical Research ,Digestive Diseases ,Hypertension ,Clinical Trials and Supportive Activities ,Kidney Disease ,Liver Disease ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Humans ,Angiotensin II ,Liver Transplantation ,End Stage Liver Disease ,Severity of Illness Index ,Living Donors ,Vasoconstrictor Agents ,Hypotension ,Norepinephrine ,Double-Blind Method ,Catecholamines ,Randomized Controlled Trials as Topic ,Multicenter Studies as Topic ,Vasoconstrictor agents ,Liver Cirrhosis ,Blood Pressure ,Public Health and Health Services ,Other Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
IntroductionCatecholamine vasopressors such as norepinephrine are the standard drugs used to maintain mean arterial pressure during liver transplantation. At high doses, catecholamines may impair organ perfusion. Angiotensin II is a peptide vasoconstrictor that may improve renal perfusion pressure and glomerular filtration rate, a haemodynamic profile that could reduce acute kidney injury. Angiotensin II is approved for vasodilatory shock but has not been rigorously evaluated for treatment of hypotension during liver transplantation. The objective is to assess the efficacy of angiotensin II as a second-line vasopressor infusion during liver transplantation. This trial will establish the efficacy of angiotensin II in decreasing the dose of norepinephrine to maintain adequate blood pressure. Completion of this study will allow design of a follow-up, multicentre trial powered to detect a reduction of organ injury in liver transplantation.Methods and analysisThis is a double-blind, randomised clinical trial. Eligible subjects are adults with a Model for End-Stage Liver Disease Sodium Score ≥25 undergoing deceased donor liver transplantation. Subjects are randomised 1:1 to receive angiotensin II or saline placebo as the second-line vasopressor infusion. The study drug infusion is initiated on reaching a norepinephrine dose of 0.05 µg kg-1 min-1 and titrated per protocol. The primary outcome is the dose of norepinephrine required to maintain a mean arterial pressure ≥65 mm Hg. Secondary outcomes include vasopressin or epinephrine requirement and duration of hypotension. Safety outcomes include incidence of thromboembolism within 48 hours of the end of surgery and severe hypertension. An intention-to-treat analysis will be performed for all randomised subjects receiving the study drug. The total dose of norepinephrine will be compared between the two arms by a one-tailed Mann-Whitney U test.Ethics and disseminationThe trial protocol was approved by the local Institutional Review Board (#20-30948). Results will be posted on ClinicalTrials.gov and published in a peer-reviewed journal.Trial registration numberClinicalTrials.govNCT04901169.
- Published
- 2023